Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00128661
First received: August 8, 2005
Last updated: May 24, 2012
Last verified: May 2012
Results First Received: December 15, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Conditions: Cervical Cancer
Precancerous Condition
Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
Biological: hepatitis A inactivated virus vaccine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Solicited symptoms were collected for 3730 and 3740 subjects instead of the 3727 and 3739 subjects who were randomized in the study in the Cervarix and the Havrix groups, respectively. These 4 sujects received both vaccines and were included in the denominator of both arm based on the actual vaccine type administered.

Reporting Groups
  Description
Cervarix Group Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
Havrix Group Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.

Participant Flow:   Overall Study
    Cervarix Group     Havrix Group  
STARTED     3727     3739  
COMPLETED     3453     3481  
NOT COMPLETED     274     258  
Adverse Event                 14                 11  
Lost to Follow-up                 10                 7  
Withdrawal by Subject                 243                 232  
Unspecified                 7                 8  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cervarix Group Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
Havrix Group Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
Total Total of all reporting groups

Baseline Measures
    Cervarix Group     Havrix Group     Total  
Number of Participants  
[units: participants]
  3727     3739     7466  
Age  
[units: Years]
Mean ± Standard Deviation
     
Years     21.1  ± 2.3     21.1  ± 2.3     21.1  ± 2.3  
Gender  
[units: Subjects]
     
Female     3727     3739     7466  
Male     0     0     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.   [ Time Frame: From Month 6 up to Month 48 ]

2.  Secondary:   Number of Cervical Infection With HPV16 or HPV18.   [ Time Frame: From Month 6 up to Month 48 ]

3.  Secondary:   Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type   [ Time Frame: From Month 6 up to Month 48 ]

4.  Secondary:   Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases   [ Time Frame: From Month 6 up to Month 48 ]

5.  Secondary:   Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.   [ Time Frame: Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48 ]

6.  Secondary:   Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort   [ Time Frame: Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48 ]

7.  Secondary:   HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)   [ Time Frame: Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48 ]

8.  Secondary:   HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)   [ Time Frame: Before vaccination and at Month 1, 6, 7, 12, 18, 24, 30, 36, 42 and 48 ]

9.  Secondary:   Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.   [ Time Frame: Within 60 minutes after vaccination ]

10.  Secondary:   Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.   [ Time Frame: Within 60 minutes after vaccination ]

11.  Secondary:   Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.   [ Time Frame: From Day 3 to Day 6 after vaccination ]

12.  Secondary:   Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.   [ Time Frame: From Day 3 to Day 6 after vaccination ]

13.  Secondary:   Number of Subjects Reporting Serious Adverse Events (SAEs).   [ Time Frame: During the entire study period (From Month 0 up to Month 48). ]

14.  Secondary:   Number of Subjects Reporting Unsolicited Adverse Events (AEs).   [ Time Frame: During the entire study period (From Month 0 up to Month 48). ]

15.  Secondary:   Number of Subjects With All Possible Pregnancy Outcomes   [ Time Frame: During the entire study period (From Month 0 up to Month 48). ]

16.  Secondary:   Number of Cervical Infection With HPV16 or HPV18.   [ Time Frame: During the first year of follow-up period ]

17.  Secondary:   Number of Cervical Infection With HPV16 or HPV18.   [ Time Frame: During the second year of follow-up period ]

18.  Secondary:   Number of Cervical Infection With HPV16 or HPV18.   [ Time Frame: During the third year of follow-up period ]

19.  Secondary:   Number of Cervical Infection With HPV16 or HPV18.   [ Time Frame: From the fourth year follow-up period ]

20.  Secondary:   Number of Subjects Reporting Unsolicited Adverse Events (AEs).   [ Time Frame: within 30 days (Days 0-29) after vaccination ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Solicited AEs: within 60 minutes after vaccination for all subjects; From Day 3 to Day 6 post-vaccination in the subset. SAEs: From Month 0 up to Month 48. Unsolicited AEs: From Month 0 up to Month 48 and Within 30 days (Days 0-29) after vaccination
Additional Description Solicited AEs were collected and tabulated for all subjects and for a 10% random subset of participants.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Cervarix Group Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
Havrix Group Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.

Other Adverse Events
    Cervarix Group     Havrix Group  
Total, other (not including serious) adverse events      
# participants affected / at risk     1627/3730     1610/3740  
Gastrointestinal disorders      
Gastrointestinal inflammation * [3]    
# participants affected / at risk     263/3727 (7.06%)     249/3739 (6.66%)  
General disorders      
Pain † [4]    
# participants affected / at risk     1627/3730 (43.62%)     1610/3740 (43.05%)  
Redness † [4]    
# participants affected / at risk     544/3730 (14.58%)     501/3740 (13.40%)  
Swelling † [4]    
# participants affected / at risk     207/3730 (5.55%)     201/3740 (5.37%)  
Fatigue † [4]    
# participants affected / at risk     512/3730 (13.73%)     502/3740 (13.42%)  
Myalgia † [4]    
# participants affected / at risk     257/3730 (6.89%)     232/3740 (6.20%)  
Gastrointestinal † [4]    
# participants affected / at risk     191/3730 (5.12%)     171/3740 (4.57%)  
Headache † [4]    
# participants affected / at risk     714/3730 (19.14%)     718/3740 (19.20%)  
Fever † [4]    
# participants affected / at risk     472/3730 (12.65%)     477/3740 (12.75%)  
Pain † [5]    
# participants affected / at risk     202/380 (53.16%)     74/376 (19.68%)  
Swelling † [5]    
# participants affected / at risk     23/380 (6.05%)     1/376 (0.27%)  
Fatigue † [5]    
# participants affected / at risk     214/380 (56.32%)     189/376 (50.27%)  
Myalgia † [5]    
# participants affected / at risk     250/380 (65.79%)     211/376 (56.12%)  
Arthralgia † [5]    
# participants affected / at risk     44/380 (11.58%)     32/376 (8.51%)  
Gastrointestinal † [5]    
# participants affected / at risk     157/380 (41.32%)     119/376 (31.65%)  
Headache † [5]    
# participants affected / at risk     247/380 (65.00%)     242/376 (64.36%)  
Rash † [5]    
# participants affected / at risk     31/380 (8.16%)     26/376 (6.91%)  
Fever † [5]    
# participants affected / at risk     43/380 (11.32%)     37/376 (9.84%)  
Infections and infestations      
Influenza * [6]    
# participants affected / at risk     263/3727 (7.06%)     293/3739 (7.84%)  
Influenza * [3]    
# participants affected / at risk     903/3727 (24.23%)     950/3739 (25.41%)  
Vaginal infection * [3]    
# participants affected / at risk     709/3727 (19.02%)     763/3739 (20.41%)  
Vulvovaginal candidiasis * [3]    
# participants affected / at risk     714/3727 (19.16%)     678/3739 (18.13%)  
Urinary tract infection * [3]    
# participants affected / at risk     555/3727 (14.89%)     565/3739 (15.11%)  
Upper respiratory tract infection * [3]    
# participants affected / at risk     324/3727 (8.69%)     327/3739 (8.75%)  
Dengue fever * [3]    
# participants affected / at risk     174/3727 (4.67%)     190/3739 (5.08%)  
Musculoskeletal and connective tissue disorders      
Myalgia * [6]    
# participants affected / at risk     355/3727 (9.53%)     166/3739 (4.44%)  
Myalgia * [3]    
# participants affected / at risk     386/3727 (10.36%)     189/3739 (5.05%)  
Nervous system disorders      
Headache * [6]    
# participants affected / at risk     218/3727 (5.85%)     214/3739 (5.72%)  
Headache * [3]    
# participants affected / at risk     324/3727 (8.69%)     315/3739 (8.42%)  
Reproductive system and breast disorders      
Menstruation irregular * [3]    
# participants affected / at risk     1021/3727 (27.39%)     1011/3739 (27.04%)  
Events were collected by systematic assessment
* Events were collected by non-systematic assessment
[3] From Month 0 up to Month 48
[4] Within 60 minutes after vaccination.
[5] From Day 3 to Day 6 post-vaccination, in a 10% random subset of participants.
[6] Within 30 days (Days 0-29) after vaccination



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The following analysis "occurence of histopathologically confirmed CIN2+ cases associated with HPV16 or HPV18 infection was not performed, in accordance with the Statistical Analysis Plan submitted to the FDA.  


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


Publications:
Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011;29:2011-4. PMC3046309

Publications automatically indexed to this study:


Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00128661     History of Changes
Obsolete Identifiers: NCT00344357
Other Study ID Numbers: CDR0000441189, NCI-04-C-N191, NCI-590299/009, GSK-590299/009
Study First Received: August 8, 2005
Results First Received: December 15, 2011
Last Updated: May 24, 2012
Health Authority: United States: Food and Drug Administration